AVBP

10.5206.57%
JA

John A. Hohneker

Independent Director

Dr. John A. Hohneker, MD, is Director of ArriVent BioPharma, Inc. since May 2024. He serves as Director at Trishula Therapeutics Inc. He is Director of Artios Pharma Limited from November 2024. He served as an Independent Director at Carisma Therapeutics, Inc. since April 01, 2024 until October 15, 2025. He serves as an Independent Director at Curis, Inc since December 2021. Dr. Hohneker joined the Curis, Inc. in December 2021. He serves as Member of Scientific Advisory Board at OnCusp Therapeutics Inc. He serves as Director at Cygnal Therapeutics, Inc. He serves as Director at BioTheryX, Inc. since August 2021. He was an Independent Director at Humanigen, Inc. since October 19, 2021 until July 18, 2023. He had been Director at Aravive, Inc. since May 12, 2021 until January 17, 2024. He servesa s Director at Cygnal Therapeutics, Inc. and Trishula Therapeutics. He had been President and Chief Executive Officer of Anokion SA since January 22, 2018 until February 2021. He served as Director at Evelo Biosciences, Inc. since January 27, 2021 until July 11, 2023. He was President of Research & Development at FORMA Therapeutics, Inc. from August 2015 to January 2018. Dr. Hohneker served as Executive Vice President and Head of Research & Development at FORMA Therapeutics, Inc. where he guided transition from a discovery stage biotech to one with multiple programs in clinical trials since July 22, 2015 until May 19, 2017. Dr. Hohneker held various leadership positions at Novartis from 2001 to 2015. He served as Senior Vice President and Global Head of Development, Immunology and Dermatology at Novartis Pharmaceuticals Corporation, where he was responsible for the global development of the immunology, rheumatology and dermatology product pipelines including the recent approvals and launches of Cosentyx, Xolair and Ilaris. Previously he served as Senior Vice President of U.S. Oncology Clinical Development and Medical Affairs where he played a key role in the development, approval and commercialization of several important oncology products such as Gleevec, Tasigna, Zometa, Afinitor and Exjade. Prior to joining Novartis, Dr. Hohneker worked at Glaxo Wellcome and its legacy company Burroughs Wellcome which includes: Worldwide Therapeutic Head, Director, Oncology Clinical Development and led the approval of Navelbine. Dr. Hohneker served as a Director at Dimension Therapeutics, Inc. since January 18, 2017 until November 7, 2017. He serves on the Board of Directors of Sonata Therapeutics, Inc. and BioTheryX Inc. He had been Director of Torque Therapeutics Inc. since March 2018. He served as Member of the Institute of Medicine Cancer Policy Forum. He served at the University of North Carolina School of Medicine at Chapel Hill, N.C. Dr. Hohneker has served on the Board of Directors of Evelo Biosciences, Inc. since January 2021. Dr. Hohneker received a B.A. in chemistry from Gettysburg College, Gettysburg, PA. and M.D. from the University of Medicine and Dentistry of New Jersey, Rutgers Medical School (Robert Wood Johnson Medical School), Piscataway, N.J. He completed his internship and residency in internal medicine and his fellowship in medical oncology all at the University of North Carolina Hospitals at Chapel Hill, N.C.

Positions